1. World Health Organization. The importance of Pharmacovigilance.Geneva: WHO 2002. |
|
2. Mann RD, Andrews EB. Introduction. In: Mann RD, Andrews EB, editors. Pharmacovigilance. London: Wiley; 2002. pp. 3–5. |
|
3. Granas AG, Buajordet M, Stenberg-Nilsen H, Harg P, Horn AM. Pharmacists' attitudes towards the reporting of suspected adverse drug reactions in Norway. Pharmacoepidemiol Drug Saf 2007; 16: 429–434. |
|
4. Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci 2008 30: 556–562. |
|
5. Cox AR, Marriott JF, Wilson KA, Ferner RE. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. J Clin Pharm Ther 2004; 29: 31–35. |
|
6. Shaw D. Toxicological risks of Chinese herbs. Planta Medica 2010, 76, 2012–2018. |
|
7. Nortier J, Vanherweghem JL. For patients taking herbal therapy –lessons from aristolochic acid nephropathy. Nephrology Dialysis and Transplantation 2007;22:1512–1517. |
|
8. World Health Organisation. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. Geneva: WHO2004. |
|
9. Delgoda R, Ellington C., Barrett S, Gordon N, Clarke N, Younger N.The practice of polypharmacy involving herbal and prescription medicines in the treatment of diabetes mellitus, hypertension and gastrointestinal disorders in Jamaica. West Indian Med J 2004; 53:400-405 [Pubmed] |
|
10. Verma S, Singh SP, Current and future status of herbal medicines. Veterinary World 2008;11:347-350. [DOI via Crossref] |
|
11. Bhanu PS, Sagar TK, Zafer R. Failure and successes of herbal medicines. The Indian Pharmacist 2000; 54: 221-235. |
|
12. Gitanjali B, Shashindran CH. Curriculum in clinical pharmacology for medical undergraduates of India. Indian J Pharmacol 2006; 38: S108–14. |
|